nivolumab

  •   George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .

  •   George Lundberg, MD

    A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

    .

  •   George Lundberg, MD

    This scientific research paper published in JAMA Oncology reports results from a clinical trial in which the drugs nivolumab and ipilimumab showed promising safety and efficacy for people with advanced liver cancer who had previously received the drug sorafenib.

    .

  •   George Lundberg, MD

    Research highlight from Nature Reviews Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    In a clinical trial for metastatic melanoma patients, a combination of the drugs nivolumab and ipilimumab (both “immune checkpoint inhibitors,” or ICIs) outperformed nivolumab on its own, and nivolumab on its own outperformed a placebo.

    Go to full research highlight published by Nature Reviews Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    In a large clinical trial for recurrent glioblastoma, treatment with the drug nivolumab, a PD-1 inhibitor, performed no better than standard-of-care treatment with the drug bevacizumab.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Eighty percent of ovarian cancers are first diagnosed after they have already spread. In the clinical trial discussed in this paper, a combination of two checkpoint inhibitor immunotherapy drugs showed only modest benefit in advanced ovarian cancer.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    What’s New in Immunotherapy for Non-Small Cell Lung Cancer?

    Emma Shtivelman, PhD

    Chemotherapy was once the only treatment option for metastatic non-small cell lung cancer (NSCLC). But five years ago, immunotherapy—treatment that boosts a patient’s own immune system to fight cancer—came on the scene. In 2015, the U.S. Food and Drug Administration… Read more »

  •   George Lundberg, MD

    Research paper from The Lancet curated by Editor in Chief George Lundberg, MD, who notes: 

    In this clinical trial, nivolumab was somewhat superior to chemotherapy for advanced esophageal carcinoma.

    Go to full paper published in The Lancet.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from Medscape:

    “Combined immunotherapy with two checkpoint inhibitors — nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) — has shown ‘clinically meaningful’ efficacy in patients with asymptomatic, untreated melanoma metastases to the brain, according to a report regarding new data from the CheckMate 204 open-label phase 2 study.

    ” ‘Although current practice is to start with surgery, stereotactic radiotherapy, or both followed by immunotherapy or targeted agents, our results support the initiation of immunotherapy to achieve prompt control of both extracranial and brain metastases,’ write the authors.”

    Go to full article published by Medscape on Aug 22, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from The ASCO Post:

    “Today, nivolumab (Opdivo) received approval from the U.S. Food and Drug Administration (FDA) for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been granted under accelerated approval based on overall response rate and duration of response.

    “This approval for nivolumab had been granted Priority Review from the FDA. It was based on data from the SCLC cohort of the ongoing phase I/II CheckMate-032 study evaluating nivolumab monotherapy in patients who experienced disease progression after platinum-based chemotherapy.”

    Go to full article published by The ASCO Post on Aug 17, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.